Jaguar Health Reports Transformational Q1 2026 Results with 816% Revenue Growth and Operational Profit
JAGX sits 45% above its 52-week low of $2.53.
Summary
Jaguar Health announced a significant Q1 2026 financial turnaround, reporting an 816% revenue increase and a swing to operational profit, largely due to a $19 million licensing deal.
Key Events · Earnings and Guidance · JAGX
-
Massive Revenue Growth
Total net revenue surged 816% year-over-year to $20.3 million in Q1 2026, primarily driven by a $19 million licensing agreement with Future Pak for Mytesi and Canalevia-CA1 U.S. commercial rights.
-
Swing to Operational Profitability
The company reported income from operations of $10.2 million in Q1 2026, a significant turnaround from a $9.4 million loss in Q1 2025.
-
Reduced Net Loss
Net loss attributable to common stockholders decreased by 33% to $7.1 million in Q1 2026 (pre-split), and Non-GAAP Recurring EBITDA loss decreased by 48% to $5.1 million.
-
Strategic Pivot to R&D Focus
Jaguar Health licensed U.S. commercial rights for Mytesi and Canalevia-CA1, allowing the company to strategically focus its resources on advancing crofelemer development for rare-disease intestinal failure indications.
Analysis · JAGX · Life Sciences
This filing details a dramatic financial turnaround for Jaguar Health, which recently faced delisting threats and a going concern warning. The company reported a massive 816% increase in total net revenue, primarily driven by a $19 million licensing agreement with Future Pak. This deal, representing over 1000% of the current market capitalization, has fundamentally altered the company's financial position, swinging from an operational loss to a significant profit. This provides substantial capital, significantly extends the company's cash runway, and enables a strategic focus on its core crofelemer development pipeline for rare-disease intestinal failure indications, drastically reducing immediate bankruptcy risk.
At the time of this filing, JAGX was trading at $3.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.53 to $211.75. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.